Zydus Lifesciences Sees Sharp Open Interest Surge Amid Bullish Momentum

Open Interest and Volume Dynamics

The latest data reveals that open interest (OI) in Zydus Lifesciences Ltd’s derivatives rose sharply by 2,720 contracts, a 14.22% increase from the previous figure of 19,123 to 21,843. This notable rise in OI coincided with a substantial volume of 34,772 contracts traded, underscoring strong participation from market players. The futures segment alone accounted for a value of approximately ₹39,860.88 lakhs, while options contributed an overwhelming ₹27,374.14 crores, culminating in a total derivatives value of ₹45,328.25 lakhs.

The surge in open interest alongside elevated volumes typically indicates fresh positions being established rather than existing ones being squared off. This pattern suggests that traders are actively positioning themselves, potentially anticipating a directional move in the underlying stock.

Price Performance and Market Positioning

Zydus Lifesciences Ltd’s underlying price closed at ₹988, having touched an intraday high of ₹989.90, marking a 5.39% gain during the session. The stock opened with a gap-up of 3.06% and outperformed its Pharmaceuticals & Biotechnology sector by 3.46%, as well as the Sensex, which gained 1.04% on the day. Over the past two trading sessions, the stock has delivered a cumulative return of 6.12%, reflecting sustained bullish momentum.

Technical indicators reinforce this positive trend, with the stock trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Such positioning typically signals strong underlying demand and a favourable medium to long-term outlook.

However, it is noteworthy that delivery volume on 13 May fell by 14.05% compared to the five-day average, registering 3.44 lakh shares. This decline in investor participation at the delivery level may indicate that short-term traders and institutional participants are driving the recent price action rather than retail investors holding for the long term.

Mojo Score Upgrade and Market Capitalisation

Reflecting the recent positive developments, MarketsMOJO upgraded Zydus Lifesciences Ltd’s mojo grade from Sell to Hold on 12 May 2026. The company currently holds a mojo score of 54.0, indicating a moderate outlook with potential for further improvement. As a mid-cap stock with a market capitalisation of ₹98,239 crore, Zydus Lifesciences commands significant investor interest within the Pharmaceuticals & Biotechnology sector.

Interpreting the Derivatives Activity

The sharp increase in open interest combined with rising prices and volumes suggests that market participants are predominantly taking bullish positions. The futures value of nearly ₹40,000 lakhs and the massive options value exceeding ₹27,000 crores indicate that traders are actively deploying capital in both outright futures contracts and complex options strategies.

Such positioning often points to expectations of continued upward price movement, possibly driven by favourable fundamentals, sector tailwinds, or upcoming corporate developments. The fact that the stock is trading above all major moving averages further supports the notion of a sustained uptrend.

Nevertheless, the decline in delivery volumes signals caution. It implies that while short-term speculative interest is high, longer-term investor conviction may not yet be fully established. This divergence can sometimes precede volatility or consolidation phases as the market digests new information.

Sector and Benchmark Comparison

On the day of analysis, Zydus Lifesciences outperformed its sector benchmark by 3.46% and the Sensex by 3.45 percentage points, highlighting its relative strength. The Pharmaceuticals & Biotechnology sector itself posted a modest gain of 1.57%, underscoring Zydus’s leadership within its peer group.

Such outperformance in a mid-cap stock is often a signal for investors to reassess their portfolio allocations, especially given the recent mojo grade upgrade and the strong derivatives market activity.

Investor Takeaway and Outlook

For investors and traders, the recent surge in open interest and volume in Zydus Lifesciences Ltd’s derivatives market signals an active repositioning that favours a bullish outlook. The stock’s strong price performance, supported by technical strength and mojo grade upgrade, suggests potential for further gains in the near term.

However, the dip in delivery volumes warrants a cautious approach, as it may indicate that retail investor participation is yet to catch up with speculative activity. Market participants should monitor upcoming corporate announcements, sector developments, and broader market trends to validate the sustainability of this momentum.

Given the mid-cap status and the current liquidity profile, Zydus Lifesciences remains a viable candidate for inclusion in diversified portfolios seeking exposure to the Pharmaceuticals & Biotechnology sector, provided investors remain vigilant to evolving market signals.

Summary of Key Metrics:

• Open Interest increased by 14.22% to 21,843 contracts
• Volume traded: 34,772 contracts
• Futures value: ₹39,860.88 lakhs
• Options value: ₹27,374.14 crores
• Underlying price: ₹988
• Intraday high: ₹989.90 (+5.39%)
• Mojo Score: 54.0 (Hold, upgraded from Sell on 12 May 2026)
• Market cap: ₹98,239 crore (Mid-cap)
• Outperformance vs sector: +3.46%
• Outperformance vs Sensex: +3.45%

In conclusion, the derivatives market activity in Zydus Lifesciences Ltd reflects a growing bullish sentiment, supported by strong price action and technical indicators. Investors should weigh these factors alongside delivery volume trends and sector dynamics to make informed decisions.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →